Indian Pharma
Latest news, explainers and analysis on Indian Pharma. Tracking 4 stories on Arth Vani.
Connected in the graph
Latest on Indian Pharma
Sun Pharma to Cut US Drug Prices Amid Affordability Drive; Analysts See Limited Impact
Sun Pharmaceutical Industries has agreed to lower its drug prices in the United States, aligning them with other developed nations as part of an initiative to enhance healthcare affordability for low-income Americans. Despite the company's substantial US revenue, financial analysts believe this move will have only a minimal impact on Sun Pharma's overall financial performance.
ChrysCapital Takes Controlling Stake in Novartis India; New CEO Appointed
Indian private equity firm ChrysCapital has acquired a controlling stake in Novartis India Limited, marking its first majority-controlled investment in the country's pharmaceutical sector. As part of this significant development, a new Chief Executive Officer has been appointed to lead Novartis India.
BreakingTrump's Proposed 200% Tariff Threatens $9.7 Billion Indian Pharma Exports by 2028
Former US President Donald Trump's proposed 200% tariff on imported generic drugs could put India's significant $9.7 billion generic drug exports to the United States at risk starting 2028. Indian pharmaceutical companies have a two-year window to explore new markets and adapt, while US patients and insurers may face increased healthcare costs.
Alembic & NATCO Get USFDA Nod for Cancer Drug; Big Market Opportunity
Indian pharmaceutical firms Alembic Pharmaceuticals and NATCO Pharma have received tentative USFDA approval for a generic version of the cancer drug Olaparib. This approval opens up a significant market opportunity in the US, estimated at ₹11,660 crore, though the commercial launch is contingent on ongoing legal proceedings.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.